|
1
|
Chen Y, Ji Y, Shen L, Li Y, Ren Y, Shi H, Li Y, Wu Y. High core 1β1,3-galactosyltransferase 1 expression is associated with poor prognosis and promotes cellular radioresistance in lung adenocarcinoma. J Cancer Res Clin Oncol 2024; 150:214. [PMID: 38662050 PMCID: PMC11045595 DOI: 10.1007/s00432-024-05745-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2024] [Accepted: 04/07/2024] [Indexed: 04/26/2024]
Abstract
PURPOSE Core 1β1,3-galactosyltransferase 1 (C1GALT1) exhibits elevated expression in multiple cancers. The present study aimed to elucidate the clinical significance of C1GALT1 aberrant expression and its impact on radiosensitivity in lung adenocarcinoma (LUAD). METHODS The C1GALT1 expression and its clinical relevance were investigated through public databases and LUAD tissue microarray analyses. A549 and H1299 cells with either C1GALT1 knockdown or overexpression were further assessed through colony formation, gamma-H2A histone family member X immunofluorescence, 5-ethynyl-2'-deoxyuridine incorporation, and flow cytometry assays. Bioinformatics analysis was used to explore single cell sequencing data, revealing the influence of C1GALT1 on cancer-associated cellular states. Vimentin, N-cadherin, and E-cadherin protein levels were measured through western blotting. RESULTS The expression of C1GALT1 was significantly higher in LUAD tissues than in adjacent non-tumor tissues both at mRNA and protein level. High expression of C1GALT1 was correlated with lymph node metastasis, advanced T stage, and poor survival, and was an independent risk factor for overall survival. Radiation notably upregulated C1GALT1 expression in A549 and H1299 cells, while radiosensitivity was increased following C1GALT1 knockdown and decreased following overexpression. Experiment results showed that overexpression of C1GALT1 conferred radioresistance, promoting DNA repair, cell proliferation, and G2/M phase arrest, while inhibiting apoptosis and decreasing E-cadherin expression, alongside upregulating vimentin and N-cadherin in A549 and H1299 cells. Conversely, C1GALT1 knockdown had opposing effects. CONCLUSION Elevated C1GALT1 expression in LUAD is associated with an unfavorable prognosis and contributes to increased radioresistance potentially by affecting DNA repair, cell proliferation, cell cycle regulation, and epithelial-mesenchymal transition (EMT).
Collapse
Affiliation(s)
- Yong Chen
- Department of Medical Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Yanyan Ji
- Department of Medical Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Lin Shen
- Department of Medical Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Ying Li
- Department of Medical Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Yue Ren
- Department of Medical Oncology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Hongcan Shi
- Department of Cardiothoracic Surgery, Medical College of Yangzhou University, Yangzhou University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Yue Li
- Department of Medical Oncology, Clinical College of Dalian Medical University, Yangzhou, 225009, Jiangsu, People's Republic of China
| | - Yunjiang Wu
- Department of Thoracic Surgery, Affiliated Hospital of Yangzhou University, Yangzhou University, No. 368 Hanjiang Road, Yangzhou, 225009, Jiangsu, People's Republic of China.
| |
Collapse
|
|
2
|
Zemkollari M, Oostenbrink C, Grabherr R, Staudacher E. Molecular cloning, characterisation and molecular modelling of two novel T-synthases from mollusc origin. Glycobiology 2024; 34:cwae013. [PMID: 38366999 PMCID: PMC11005171 DOI: 10.1093/glycob/cwae013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2023] [Revised: 02/09/2024] [Accepted: 02/11/2024] [Indexed: 02/19/2024] Open
Abstract
The glycoprotein-N-acetylgalactosamine β1,3-galactosyltransferase, known as T-synthase (EC 2.4.1.122), plays a crucial role in the synthesis of the T-antigen, which is the core 1 O-glycan structure. This enzyme transfers galactose from UDP-Gal to GalNAc-Ser/Thr. The T-antigen has significant functions in animal development, immune response, and recognition processes. Molluscs are a successful group of animals that inhabit various environments, such as freshwater, marine, and terrestrial habitats. They serve important roles in ecosystems as filter feeders and decomposers but can also be pests in agriculture and intermediate hosts for human and cattle parasites. The identification and characterization of novel carbohydrate active enzymes, such as T-synthase, can aid in the understanding of molluscan glycosylation abilities and their adaptation and survival abilities. Here, the T-synthase enzymes from the snail Pomacea canaliculata and the oyster Crassostrea gigas are identified, cloned, expressed, and characterized, with a focus on structural elucidation. The synthesized enzymes display core 1 β1,3-galactosyltransferase activity using pNP-α-GalNAc as substrate and exhibit similar biochemical parameters as previously characterised T-synthases from other species. While the enzyme from C. gigas shares the same structural parameters with the other enzymes characterised so far, the T-synthase from P. canaliculata lacks the consensus sequence CCSD, which was previously considered indispensable.
Collapse
Affiliation(s)
- Marilica Zemkollari
- Department of Chemistry, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | - Chris Oostenbrink
- Department of Material Sciences and Process Engineering, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | - Reingard Grabherr
- Department of Biotechnology, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| | - Erika Staudacher
- Department of Chemistry, University of Natural Resources and Life Sciences, Muthgasse 18, 1190 Vienna, Austria
| |
Collapse
|
|
3
|
Sun L, Zhang Y, Li W, Zhang J, Zhang Y. Mucin Glycans: A Target for Cancer Therapy. Molecules 2023; 28:7033. [PMID: 37894512 PMCID: PMC10609567 DOI: 10.3390/molecules28207033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 10/08/2023] [Accepted: 10/10/2023] [Indexed: 10/29/2023] Open
Abstract
Mucin glycans are an important component of the mucus barrier and a vital defence against physical and chemical damage as well as pathogens. There are 20 mucins in the human body, which can be classified into secreted mucins and transmembrane mucins according to their distributions. The major difference between them is that secreted mucins do not have transmembrane structural domains, and the expression of each mucin is organ and cell-specific. Under physiological conditions, mucin glycans are involved in the composition of the mucus barrier and thus protect the body from infection and injury. However, abnormal expression of mucin glycans can lead to the occurrence of diseases, especially cancer, through various mechanisms. Therefore, targeting mucin glycans for the diagnosis and treatment of cancer has always been a promising research direction. Here, we first summarize the main types of glycosylation (O-GalNAc glycosylation and N-glycosylation) on mucins and the mechanisms by which abnormal mucin glycans occur. Next, how abnormal mucin glycans contribute to cancer development is described. Finally, we summarize MUC1-based antibodies, vaccines, radio-pharmaceuticals, and CAR-T therapies using the best characterized MUC1 as an example. In this section, we specifically elaborate on the recent new cancer therapy CAR-M, which may bring new hope to cancer patients.
Collapse
Affiliation(s)
- Lingbo Sun
- Medical College of Yan'an University, Yan'an University, Yan'an 716000, China
| | - Yuhan Zhang
- Medical College of Yan'an University, Yan'an University, Yan'an 716000, China
| | - Wenyan Li
- Medical College of Yan'an University, Yan'an University, Yan'an 716000, China
| | - Jing Zhang
- Medical College of Yan'an University, Yan'an University, Yan'an 716000, China
| | - Yuecheng Zhang
- Key Laboratory of Analytical Technology and Detection of Yan'an, College of Chemistry and Chemical Engineering, Yan'an University, Yan'an 716000, China
| |
Collapse
|
|
4
|
dos Reis JS, Rodrigues da Costa Santos MA, Mendonça DP, Martins do Nascimento SI, Barcelos PM, Correia de Lima RG, da Costa KM, Freire-de-Lima CG, Morrot A, Previato JO, Mendonça Previato L, da Fonseca LM, Freire-de-Lima L. Glycobiology of Cancer: Sugar Drives the Show. MEDICINES 2022; 9:medicines9060034. [PMID: 35736247 PMCID: PMC9229842 DOI: 10.3390/medicines9060034] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/26/2022] [Revised: 05/19/2022] [Accepted: 05/20/2022] [Indexed: 11/16/2022]
Abstract
Cancer development and progression is associated with aberrant changes in cellular glycosylation. Cells expressing altered glycan-structures are recognized by cells of the immune system, favoring the induction of inhibitory immune processes which subsequently promote tumor growth and spreading. Here, we discuss about the importance of glycobiology in modern medicine, taking into account the impact of altered glycan structures expressed in cancer cells as potential glycobiomarkers of disease, as well as on cancer development and progression.
Collapse
Affiliation(s)
- Jhenifer Santos dos Reis
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Marcos André Rodrigues da Costa Santos
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Daniella Pereira Mendonça
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Stefani Ingrid Martins do Nascimento
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Pedro Marçal Barcelos
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Rafaela Gomes Correia de Lima
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Kelli Monteiro da Costa
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Celio Geraldo Freire-de-Lima
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Alexandre Morrot
- Instituto Oswaldo Cruz, FIOCRUZ, Rio de Janeiro 21040-360, Brazil;
- Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21044-020, Brazil
| | - Jose Osvaldo Previato
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Lucia Mendonça Previato
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Leonardo Marques da Fonseca
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
| | - Leonardo Freire-de-Lima
- Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-170, Brazil; (J.S.d.R.); (M.A.R.d.C.S.); (D.P.M.); (S.I.M.d.N.); (P.M.B.); (R.G.C.d.L.); (K.M.d.C.); (C.G.F.-d.-L.); (J.O.P.); (L.M.P.); (L.M.d.F.)
- Correspondence: ; Tel./Fax: +55-21-3938-6646
| |
Collapse
|